BCLS ACQUISITION CORP's ticker is BLSA and the CUSIP is G0904B105. A total of 46 filers reported holding BCLS ACQUISITION CORP in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $4,885,000 | +1.2% | 487,500 | 0.0% | 0.58% | +3.0% |
| Q2 2022 | $4,826,000 | +0.3% | 487,500 | 0.0% | 0.57% | +21.2% |
| Q1 2022 | $4,812,000 | +0.7% | 487,500 | 0.0% | 0.47% | +23.2% |
| Q4 2021 | $4,778,000 | -1.6% | 487,500 | 0.0% | 0.38% | +25.9% |
| Q3 2021 | $4,856,000 | -5.4% | 487,500 | 0.0% | 0.30% | -10.4% |
| Q2 2021 | $5,133,000 | -0.4% | 487,500 | 0.0% | 0.34% | +15.1% |
| Q1 2021 | $5,153,000 | -5.1% | 487,500 | 0.0% | 0.29% | -14.4% |
| Q4 2020 | $5,431,000 | – | 487,500 | – | 0.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 843,122 | $8,347,000 | 4.65% |
| Logan Stone Capital, LLC | 175,698 | $1,739,000 | 1.28% |
| Samsara BioCapital, LLC | 300,000 | $2,970,000 | 0.79% |
| Bain Capital Life Sciences Investors, LLC | 487,500 | $4,826,000 | 0.57% |
| COMMODORE CAPITAL LP | 250,000 | $2,475,000 | 0.52% |
| Altium Capital Management LP | 100,000 | $990,000 | 0.40% |
| Exos Asset Management LLC | 70,367 | $697,000 | 0.36% |
| RA Capital Management | 1,250,000 | $12,375,000 | 0.33% |
| Boxer Capital, LLC | 500,000 | $4,950,000 | 0.31% |
| PFM Health Sciences, LP | 464,103 | $4,595,000 | 0.18% |